U.S. Markets close in 2 hrs 46 mins
  • S&P 500

    3,469.85
    -13.96 (-0.40%)
     
  • Dow 30

    28,523.98
    -82.33 (-0.29%)
     
  • Nasdaq

    11,643.63
    -27.93 (-0.24%)
     
  • Russell 2000

    1,637.13
    +3.32 (+0.20%)
     
  • Crude Oil

    40.94
    +0.06 (+0.15%)
     
  • Gold

    1,913.10
    +6.70 (+0.35%)
     
  • Silver

    24.72
    +0.31 (+1.27%)
     
  • EUR/USD

    1.1787
    +0.0059 (+0.5068%)
     
  • 10-Yr Bond

    0.7590
    +0.0150 (+2.02%)
     
  • Vix

    27.85
    +0.44 (+1.61%)
     
  • GBP/USD

    1.2983
    +0.0074 (+0.5764%)
     
  • USD/JPY

    105.3810
    -0.0130 (-0.0123%)
     
  • BTC-USD

    11,756.26
    +699.25 (+6.32%)
     
  • CMC Crypto 200

    239.84
    +6.17 (+2.64%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Old fare as well as young in Moderna vaccine trial

Moderna's experimental COVID-19 vaccine induced immune responses in older adults that were similar to younger participants.

Results from the early small-scale clinical trial –released Wednesday - keeps Moderna in the race as one of the leading U.S. contenders to develop a vaccine against the novel coronavirus.

The analysis looked at a 100 microgram dosage and found the immune responses in those aged between 56 and 70 years, above 70 and those in the age-group of 18 and 55 were similar.

Moderna is already moving on to a larger late-stage clinical trial, where it has signed up more than 13,000 people to take part.

The pressure is on Moderna to come up with a winner. Even though it doesn't have any drugs on the market, the U.S. government gave Moderna nearly $1 billion towards a vaccine development. It also struck a $1.5 billion supply agreement with the company.

Investors have responded by betting big on the stock - shares have tripled in value so far this year. The stock moved higher still on Wednesday - up by as much as 7 percent in early trading.

Video Transcript

- Moderna's experimental COVID-19 vaccine induced immune responses in older adults that were similar to younger participants. Results from the early small scale clinical trial released Wednesday keeps Moderna in the race as one of the leading US contenders to develop a vaccine against the novel coronavirus. The analysis looked at a 100 microgram dosage and found the immune responses in those aged between 56 and 70 years old above 70 and those in the age group of 18 and 55 similar.

Moderna's already moving onto a larger late stage clinical trial, which it has signed up more than 13,000 people to take part. The pressure is on Moderna to come up with a winner. Even though it doesn't have any drugs on the market, the US government gave Moderna nearly $1 billion towards a vaccine development. It also struck at $1.5 1/2 billion supply agreement with the company. Investors have responded by betting big on the stock. Shares have tripled in value so far this year. The stock moved higher still on Wednesday, up by as much as 7% in early trading.